Progress in the understanding of the biology and therapy of acute myeloid leukemia (AML)
is occurring rapidly. Since 2017, nine agents have been approved for various indications in …

With rapid advances in sequencing technologies, tremendous progress has been made in
understanding the molecular pathogenesis of acute myeloid leukaemia (AML), thus …

Until recently, acute myeloid leukemia (AML) patients used to have limited treatment options,
depending solely on cytarabine+ anthracycline (7+ 3) intensive chemotherapy and …

The unraveling of the pathophysiology of acute myeloid leukemia (AML) has resulted in
rapid translation of the information into clinical practice. After more than 40 years of slow …

Venetoclax is a highly selective and effective B-cell lymphoma-2 (BCL-2) inhibitor, which is
able to reinstate the apoptotic potential of cancer cells. With its full repertoire yet to be …

Patients with relapsed or refractory (r/r) acute myeloid leukemia (AML) have a poor
prognosis and treatment remains challenging. For the majority of r/r patients, allogeneic …

Mutations of Nucleophosmin (NPM1) are the most common genetic abnormalities in adult
acute myeloid leukaemia (AML), accounting for about 30% of cases. NPM1-mutated AML …

Over the past two decades, the prognosis in adolescents and young adults (AYAs)
diagnosed with acute myeloid leukemia (AML) has significantly improved. The standard …

Preclinical data suggest a rationale for combining CPX-351, a dual-drug liposomal
encapsulation of daunorubicin and cytarabine, with venetoclax, a B-cell lymphoma-2 …

BCL-2 inhibition has transformed the therapeutic landscape of acute myeloid leukemia
(AML) but is not curative for the majority of patients. Consequently, there has been growing …